• Innovative Company SHIONOGI

What's New

  • Show All
2017/06/22
Shionogi to Issue of Stock Options as Compensation (Stock Acquisition Rights) to Members of Board of Directors
2017/06/12
Shionogi concluded a non-exclusive contract with PeptiDream
2017/06/07
Opioid-Induced Constipation therapeutic agent ‘Symproic® (naldemedine) Tablets 0.2mg’ launched in Japan
2017/06/02
FURTHER EVIDENCE SUPPORTS CEFIDEROCOL ACTIVITY AGAINST MDR GRAM-NEGATIVE PATHOGENS: DATA PRESENTED AT THE AMERICAN SOCIETY FOR MICROBIOLOGY MICROBE (ASM) MEETING
2017/06/01
Shionogi contributes to the second phase of the Global Health Innovative Technology Fund
2017/05/26
Attention deficit/hyperactivity disorder (AD/HD) therapeutic agent ‘INTUNIV® Tablets 1 mg/3 mg’ launched in Japan
2017/05/18
Audio Webcasting of FY2016 Financial Results
2017/05/10
FY2016 Financial Results
2017/04/25
Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
2017/04/25
Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin
2017/04/24
Notice of Revisions to Dividend Forecasts
2017/04/18
Shionogi to Present New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin, and S-033188 a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
2017/04/13
Regarding the Application for Manufacture and Sales Approval of “Lisdexamfetamine Dimesylate”, a Therapeutic Agent for Attention Deficit Hyperactivity Disorder